Welcome to our dedicated page for Quantum-Si SEC filings (Ticker: QSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Quantum-Si's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Quantum-Si's regulatory disclosures and financial reporting.
Quantum-Si Inc director Kevin Rakin received a grant of stock options for 251,185 shares of Class A common stock at an exercise price of $0.8539 per share. These options expire on May 18, 2036 and vest on the date of the issuer's next regular annual stockholders meeting, subject to continued service.
Following the reported transactions, Rakin holds 20,512 Class A shares directly and 1,200,000 shares indirectly through investment entities with which he shares voting and investment discretion. The new option award adds to this equity exposure as compensation rather than an open‑market purchase.
Quantum-Si Inc director Scott Mendel reported an equity award. He received a grant of 251,185 stock options to buy Class A Common Stock at an exercise price of $0.8539 per share, expiring on May 18, 2036.
The options cover 251,185 underlying Class A shares and vest on the date of Quantum-Si’s next regular annual stockholders meeting, subject to his continued service through that vesting date. After this filing, he directly holds 141,843 shares of Class A Common Stock and 251,185 options.
ROTHBERG JONATHAN M reported acquisition or exercise transactions in this Form 4 filing.
Quantum-Si Inc director and 10% owner Jonathan M. Rothberg reported a grant of 251,185 stock options, each exercisable for one share of Class A Common Stock at $0.8539 per share. The options vest on the date of the issuer’s next regular annual stockholders meeting, subject to his continued service.
After this grant, he holds 2,568,443 Class A Common Stock shares directly and has additional indirect holdings, including 1,993,750 Class B shares through 4C Holdings V, LLC and 17,943,750 Class B shares through 4C Holdings I, LLC. Some shares are held by entities managed by Dr. Rothberg and by family members, and he disclaims beneficial ownership of shares held by his spouse and by 23rd Century Capital LLC.
Quantum-Si Inc director Charles R. Kummeth reported a new equity award and updated holdings. He received a grant of 251,185 stock options, each giving the right to buy one share of Class A Common Stock at an exercise price of $0.8539 per share. These options expire on May 18, 2036 and the shares underlying the option vest on the date of the issuer's next regular annual stockholders meeting, subject to continued service through that vesting date. Following this filing, he directly holds 855,000 shares of Class A Common Stock, alongside the newly granted options. This award is compensation-related and does not reflect an open-market purchase or sale.
-SI Incorporated reported voting results from its Annual Meeting held on May 15, 2026. Shareholders representing approximately 84.59% of the total voting power of Class A and Class B shares formed a quorum.
All nominated directors were reelected, with Jonathan M. Rothberg, Ph.D. receiving 454,010,014 votes for and 429,631 against. Shareholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm, with 502,452,749 votes for, and approved the advisory vote on executive compensation with 441,315,119 votes for.
Quantum-Si Incorporated reported Q1 2026 results showing sharply lower revenue and continued investment in proteomics R&D. Total revenue was $258 thousand, down 69.4% from $842 thousand a year earlier, mainly because customers delayed instrument and consumable purchases ahead of the anticipated Proteus platform launch by the end of 2026.
Gross profit fell to $74 thousand and gross margin declined to 28.7% from 57.7% as product mix and lower volumes weighed on profitability. Research and development expenses rose 5.6% to $14.5 million, reflecting higher lab supplies, payroll and outsourced work to advance Proteus, while selling, general and administrative costs fell 18.9% to $9.6 million due to lower legal, payroll and marketing spend.
The company recorded a net loss of $21.7 million, compared with a $19.2 million net loss in Q1 2025, and used $25.6 million in operating cash. As of March 31, 2026, Quantum-Si held $190.4 million of cash, cash equivalents and marketable securities, which management believes is sufficient to fund planned operations for at least the next twelve months.
Quantum-Si Incorporated reported first quarter 2026 results and updated its 2026 outlook. Revenue for the quarter was $258,000, generating gross profit of $74,000 and a gross margin of 29%. Net loss was $21.7 million, while adjusted EBITDA was negative $20.1 million.
Adjusted total operating expenses were $21.4 million, down from $22.9 million a year earlier as the company managed selling, general and administrative costs while increasing research and development for its Proteus platform. Cash, cash equivalents and marketable securities totaled $190.4 million as of March 31, 2026, which the company anticipates will fund operations into the second quarter of 2028.
For full-year 2026, Quantum-Si reiterated guidance of approximately $1.0 million in revenue, adjusted total operating expenses of $98.0 million or less, and total cash usage of $93.0 million or less, reflecting a transition year focused on preparing the Proteus single-molecule protein sequencing system for an anticipated commercial launch at the end of 2026.
Quantum-Si Inc Chief Financial Officer Jeffry R. Keyes reported mandatory tax-related share sales. He sold 37,382 shares of Class A Common Stock on April 20, 2026 at a weighted average price of $1.0064 per share and 37,381 shares on April 21, 2026 at a weighted average price of $0.9950 per share.
According to the footnotes, both transactions were executed under a mandatory Quantum-Si sell-to-cover provision to satisfy federal, state and local withholding taxes associated with vesting restricted stock units, and he could not alter this provision. After these transactions, he directly owns 1,732,582 Class A shares.
Quantum-Si Inc President & CEO Jeffrey Alan Hawkins reported two open-market sales of Class A Common Stock tied to tax withholding. He sold 83,712 shares on April 20, 2026 at a weighted average price of $1.0064 per share and another 83,712 shares on April 21, 2026 at a weighted average price of $0.9950 per share. According to the disclosure, these transactions were executed under a mandatory sell-to-cover provision to satisfy federal, state and local withholding taxes triggered by the vesting of previously granted restricted stock units. After these sales, Hawkins directly owned 3,692,423 shares of Quantum-Si Class A Common Stock.
Quantum-Si Incorporated notice of proposed sale of 187,500 Class A Common Stock linked to Restricted Stock Unit Vesting on 04/22/2026. The filing also records 8,655 shares sold on 03/20/2026 by Morgan Stanley Smith Barney LLC as shown. The securities are described as equity compensation for services rendered.